Upstream Bio's CEO Rand Sutherland discusses today's severe asthma data for verekitug, a TSLP receptor antagonist
BiotechTV - News
00:00
Related programs: CRS, COPD updates
Rand explains using both asthma and CRS data for joint phase 3 planning and progress on the COPD trial.
Play episode from 11:20
Transcript
